Zhong Jin Zai Xian·2026-03-02 02:54Core Viewpoint - Fosun International (00656.HK) announced a share buyback plan with a total amount not exceeding HKD 1 billion, citing that the current stock price does not reflect the company's long-term value and expressing confidence in its future development [1] Group 1: Business Performance - In 2026, Fosun's core sectors, including biomedicine, cultural tourism, and insurance, continue to show strong momentum [2] - The biopharmaceutical sector has made significant strides, with a partnership with Eisai Co., Ltd. for H drug Hansai in Japan, potentially worth over USD 300 million, and a global exclusive licensing agreement with Pfizer valued at over USD 2 billion [2] - In cultural tourism, Fosun's various product lines have performed well, with Shanghai Yuyuan receiving nearly 1.2 million visitors during the Spring Festival, a year-on-year increase of over 20%, and Atlantis Sanya achieving a record revenue of RMB 124 million during the holiday, up 20% year-on-year [2] Group 2: Insurance Sector Growth - Fosun's domestic insurance companies reported significant growth in 2025, with Fosun United Health Insurance achieving revenue of RMB 7.84 billion, a 50% increase, and Fosun Puhui Life Insurance reporting revenue of RMB 12.598 billion, a 36.17% increase, with net profit soaring over 450% to RMB 647 million [3] - The robust growth in core businesses is seen as a catalyst for the share buyback, with improved asset structure and clear growth logic justifying a more reasonable market valuation [3] Group 3: Share Buyback Details - Fosun International previously repurchased 13.027 million shares for HKD 48.2354 million on February 27, and has cumulatively repurchased 258.859 million shares since January 1, 2022, accounting for 3.17% of total issued shares, with a total expenditure of approximately HKD 1.19 billion [3] - The announcement emphasized that the buyback aligns with the overall interests of the company and its shareholders at the current valuation level [4]